Dec 01, 2020 / 03:30PM GMT
Vijay Muniyappa Kumar - Evercore ISI Institutional Equities, Research Division - MD
Okay. Thanks, everyone, for joining us for this morning's session with Zimmer Biomet. I'm Vijay Kumar, I cover devices, life sciences at Evercore. Very pleased to have with us Bryan Hanson, CEO; Suky Upadhyay, CFO; and representing the IR team, we have Keri Mattox. Gentlemen, ladies, thank you for joining us.
Questions and Answers:
Vijay Muniyappa Kumar - Evercore ISI Institutional Equities, Research Division - MDMaybe I'll start with something, which has been topical, Bryan, and it shouldn't be a surprise, second wave has been topical when I -- if I look back at your 3Q commentary, you said October was in line with 3Q, except for EMEA. Perhaps talk about what kind of impact, if any, the second wave was having on the business as you see now.
Bryan C. Hanson - Zimmer Biomet Holdings, Inc. - President, CEO & Director
Sure. So clearly, it's having an impact. But what I'll do maybe is toss this over to Suky, he's the on the